Summit Therapeutics holders approve raising authorized common stock to 2 billion shares
On November 4, 2026, Summit Therapeutics stockholders approved raising authorized common shares from 1 billion to 2 billion at a special meeting, and the amendment took effect when filed that day. The same day, the company reported third-quarter 2026 results showing a GAAP net loss of $208.4 million ($0.26 per share), narrower than $231.8 million a year earlier, while the non-GAAP net loss widened to $160.7 million from $101.0 million. Cash and short-term investments were $629.8 million at September 30, 2026, and the $2.0 billion AstraZeneca equity investment completed October 5, 2026, after the quarter ended.
Key points
- Amendment No. 3 increases authorized common stock by 1,000,000,000 shares to 2,000,000,000; votes for were 658,142,561, against 1,983,511, with 3,134,826 abstentions.
- GAAP net loss was $208.4 million, or $(0.26) per share, versus $231.8 million, or $(0.31) per share, a year earlier; non-GAAP net loss was $160.7 million, or $(0.20) per share, versus $101.0 million, or $(0.13).
- Cash and short-term investments were $629.8 million at September 30, 2026, down from $713.4 million at December 31, 2025; the company raised $94.1 million through its ATM facility in the third quarter.
- AstraZeneca completed a $2.0 billion strategic equity investment on October 5, 2026; the FDA PDUFA goal action date for the ivonescimab BLA is November 14, 2026.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.